Medical device firm TransEnterix has signed an agreement to sell the SurgiBot System and its assets to Great Belief International (GBIL).

SurgiBot System is a single-port laparoscopic surgical platform that has been robotically enhanced.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

After completion of the deal, GBIL will manufacture the system in China and obtain clearance from the Chinese Food and Drug Administration (CFDA).

The firm also plans to form a nationwide distribution agreement with China National Scientific and Instruments and Materials (CSIMC) to enhance commercial potential and optimise post-sale services for national hospitals.

TransEnterix is set to receive around $29m and will retain the option to distribute or co-distribute the system outside of China.

“We believe this relationship provides us with a significant opportunity to expand our product offerings of robotic solutions for hospitals and patients around the world.”

From the total deal, $7.5m will be paid by the end of this year, another $7.5m in March next year and the remaining $14m on receiving Chinese regulatory approval or within five years, whichever is earlier.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TransEnterix president and CEO Todd Pope said: “The relationship announced today with GBIL will allow us to advance the SurgiBot System towards global commercialisation, while significantly reducing our required investment and simultaneously leveraging in-country manufacturing in the world’s most populous country.

“We believe this relationship provides us with a significant opportunity to expand our product offerings of robotic solutions for hospitals and patients around the world.”

In October, TransEnterix obtained the FDA 510(k) clearance for its Senhance Surgical Robotic System designed to allow surgeons to precisely direct small surgical instruments.

The robotic surgery platform includes haptic feedback for security and eye-sensing camera for control.